Evaluation of Aldrithiol-2-inactivated preparations of HIV type 1 subtypes A, B, and D as reagents to monitor T cell responses

AIDS Research and Human Retroviruses

Volumn 23, Issue 4, 2007, Pages 532-542

  Rutebemberwa, A ^a   Bess Jr , J W ^b   Brown, B ^a   Arroyo, M ^a   Eller, M ^c   Slike, B ^a   Polonis, V ^a   McCutchan, F ^a   Currier, J R ^a   Birx, D ^a   Robb, M ^a   Marovich, M ^a   Lifson, J D ^b   Cox, Josephine H ^a  

^a Henry Jackson Foundation   (United States)

^b SAIC FREDERICK INC   (United States)

^c MAKERERE UNIVERSITY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ALDRITHIOL 2; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INACTIVATED VIRUS VACCINE; PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UGANDA; VIRUS INACTIVATION; VIRUS ISOLATION;

2,2'-DIPYRIDYL; AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DISULFIDES; HIV-1; HUMANS; INTERFERON TYPE II; OXIDANTS; VIRUS INACTIVATION;

EID: 34247847793     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0136     Document Type: Article

References (71)

1. Pantaleo G and Koup RA: Correlates of immune protection in HIV-1 infection: What we know, what we don't know, what we should know. Nat Med 2004;10:806-810.
2. Addo MM, Yu XG, Rathod A, et al.: Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003;77:2081-2092.
3. Betts MR, Ambrozak DR, Douek DC, et al.: Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses: Relationship to viral load in untreated HIV infection. J Virol 2001;75:11983-11991.
4. Gea-Banacloche J, Migueles S, Martino L, et al.: Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors. J Immunol 2000;165:1082-1092.
5. Jansen CA, De Cuyper IM, Hooibrink B, van der Bij AK, van Baarle D, and Miedema F: Prognostic value of HIV-1 Gag-specific CD4+ T-cell responses for progression to AIDS analysed in a prospective cohort study. Blood 2006;107:1427-1433.
6. Betts MR, Nason MC, West SM, et al.: HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T-cells. Blood 2006;107:4781-4789.
7. Borrow P, Lewicki H, Hahn BH, Shaw GM, and Oldstone MB: Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
8. Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, and Goepfert PA: Magnitude of functional CD8+ T-cell responses to the Gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 2002;76:2298-2305.
9. Koup RA, Safrit JT, Cao Y, et al.: Temporal association of cellular immune responses with the initial viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-4655.
10. Rosenberg E, Billingsley J, Caliendo A, et al.: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-1450.
11. Migueles S, Laborico A, Shupert W, et al.: HIV-specific CD8+ T cell proliferation is coupled to perform expression and is maintained in nonprogressors. Nat Immunol 2002;3:1061-1068.
12. Rowland-Jones S, Sutton J, Ariyoshi K, et al.: HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995;1:59-64.
13. Schmitz JE, Kuroda MJ, Santra S, et al.: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283:857-860.
14. Jin X, Bauer D, Tuttleton S, et al.: Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999;189:991-998.
15. McMichael A and Hanke T: The quest for an AIDS vaccine; is the CD8+ T-cell approach feasible? Nat Immunol 2002;2:283-291.
16. Robinson HL and Amara RR: T cell vaccines for microbial infections. Nat Med 2005;11:S25-32.
17. The Global HIV/AIDS Vaccine Enterprise: Scientific Strategic Plan. PLoS Med 2005;2e25:1-11.
18. De Rosa SC, Lu FX, Yu J, et al.: Vaccination in humans generates broad T cell cytokine responses. J Immunol 2004;173:5372-5380.
19. Lieberman J: Tracking the killers: How should we measure CD8 T cells in HIV infection? AIDS 2004;18:1489-1493.
20. Roederer M, Brenchley JM, Betts MR, and De Rosa SC: Flow cytometric analysis of vaccine responses: How many colors are enough? Clin Immunol 2004;110:199-205.
21. Schiller D, Binley J, Roux K, et al.: Parameters influencing measurement of the Gag antigen-specific T-proliferative response to HIV type 1 infection. AIDS Res Hum Retroviruses 2000;16:259-271.
22. Walker B, Chakrabarti S, Moss B, et al.: HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987;328:p345-348.
23. Karlsson AC, Martin JN, Younger SR, et al.: Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods 2003;283:141-153.
24. Larsson M, Jin X, Ramratnam B, et al.: A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS 1999;13:767-777.
25. Xu J, Lori F, and Lisziewicz J: Vaccinia assay for the rapid detection of functional HIV-specific CD8+ cytotoxic T lymphocytes. J Immunol Methods 2003;276:45-57.
26. Kern F, Surel I, Brock C, et al.: T-cell epitope mapping by flow cytometry. Nat Med 1998;4:975-978.
27. Roederer M and Koup RA: Optimized determination of T cell epitope responses. J Immunol Methods 2003;274:221-228.
28. Currier JR, Visawapoka U, Tovanabutra S, et al.: CTL epitope distribution patterns in the gag and nef proteins of HIV-1 from subtype A infected subjects in Kenya: Use of multiple peptide sets increases the detectable breadth of the CTL response. BMC Immunol 2006;7:8.
29. Draenert R, Verrill CL, Tang Y, et al.: Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. J Virol 2004;78:630-641.
30. Arroyo MA, Hoelscher M, Sanders-Buell E, et al.: HIV type 1 subtypes among blood donors in the Mbeya region of southwest Tanzania. AIDS Res Hum Retroviruses 2004;20:895-901.
31. Dowling W, Kim B, Mason C, et al.: Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants AIDS 2002;16:1809-1820.
32. Harris M, Serwada D, Sewankambo NK, et al.: Among 46 near full-length HIV Type 1 genome sequences from Rakai District, Uganda, subtype D and AD recombinants predominate. AIDS Res Hum Retroviruses 2002;18:1281-1290.
33. Arthur L, Bess J, Chertova E, et al.: Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: A candidate SIV vaccine. AIDS Res Hum Retroviruses 1998;14(Suppl. 3):S311-319.
34. Rossio J, Esser M, Suryanarayana K, et al.: Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 1998;72:7992-8001.
35. Frank I, Piatak M, Stoessel H, et al.: Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): Differential intracellular fate of virions in mature and immature DCs. J Virol 2002;76:2936-2951.
36. Turville SG, Santos JJ, Frank I, et al.: Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood 2004;103:2170-2179.
37. Teleshova N, Kenney J, Jones J, et al.: CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-gamma-secreting simian immunodeficiency virus-specific T cells. J Immunol 2004;173:1647-1657.
38. Zhu P, Chertova E, Bess J Jr, et al.: Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci USA 2003;100:15812-15817.
39. Buseyne F, Le Gall S, Boccaccio C, et al.: MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat Med 2001;7:344-349.
40. Fonteneau JF, Larsson M, Beignon AS, et al.: Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol 2004;78:5223-5232.
41. Larsson M, Fonteneau JF, Lirvall M, Haslett P, Lifson JD, and Bhardwaj N: Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: Roles for cross-presentation and non-infectious HIV-1 virus. AIDS 2002;16:1319-1329.
42. Schmitz JL, Denny TN, Garcia A, and Lathey JL: Comparison of human immunodeficiency virus antigens as stimulants for lymphocyte proliferation assays. Clin Diagn Lab Immunol 2002;9:525-529.
43. Hoelscher M, Dowling W, Sanders-Buell E, et al.: Detection of HIV-1 subtypes, recombinants, and dual infections in east Africa by a multi-region hybridization assay AIDS 2002;16:2055-2064.
44. Brown BK, Darden JM, Tovanabutra S, et al.: Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J Virol 2005;79:6089-6101.
45. Chertova E, Crise BJ, Morcock DR, Bess JW Jr, Henderson LE, and Lifson JD: Sites, mechanism of action and lack of reversibility of primate lentivirus inactivation by preferential covalent modification of virion internal proteins. Curr Mol Med 2003;3:265-272.
46. Draenert R, Altfeld M, Brander C, et al.: Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods 2003;275:19-29.
47. Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, and McElrath MJ: Moving to HIV-1 vaccine efficacy trials: Defining T cell responses as potential correlates of immunity. J Infect Dis 2003;187:226-242.
48. Trigona WL, Clair JH, Persaud N, et al.: Intracellular staining for HIV-specific IFN-gamma production: Statistical analyses establish reproducibility and criteria for distinguishing positive responses. J Interferon Cytokine Res 2003;23:369-377.
49. Bihl F, Frahm N, Di Giammarino L, et al.: Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 2006;176:4094-4101.
50. Coplan PM, Gupta SB, Dubey SA, et al.: Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents. J Infect Dis 2005;191:1427-1434.
51. Karlsson RK, Jennes W, Page-Shafer K, Nixon DF, and Shacklett BL: Poorly soluble peptides can mimic authentic ELISPOT responses. J Immunol Methods 2004;285:89-92.
52. Gao F, Weaver EA, Lu Z, et al.: Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein. J Virol 2005;79:1154-1163.
53. Gaschen B, Taylor J, Yusim K, et al.: Diversity considerations in HIV-1 vaccine selection. Science 2002;296:2354-2360.
54. Rutebemberwa A, Currier JR, Jagodzinski L, et al.: HIV-1 MN Env 15-mer peptides better detect HIV-1 specific CD8 T cell responses compared with consensus subtypes B and M group 15-mer peptides. AIDS 2005;19:1165-1172.
55. Day CL, Kiepiela P, Leslie AJ, et al.: Proliferative capacity of epitope-specific CD8 T cell responses is inversely related to viral load in chronic HIV-1 infection. J Virol 2007;81:434-438.
56. Goonetilleke N, Moore S, Dally L, et al.: Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 2006;80:4717-4728.
57. Keating SM, Bejon P, Berthoud T, et al.: Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol 2005;175:5675-5680.
58. Vuola JM, Keating S, Webster DP, et al.: Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 2005;174:449-455.
59. Yu J, Chen H, Horton H, et al.: Interleukin-2 reconstitutes defective human immunodeficiency virus (HIV), and cytomegalovirus (CMV) specific CD8+ T cell proliferation in HIV infection. J Med Virol 2006;78:1147-1157.
60. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart P-A, and Pantaleo G: HIV-1-specific IFN-{gamma}/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci USA 2005;102:7239-7244.
61. Frank I, Santos JJ, Mehlhop E, et al.: Presentation of exogenous whole inactivated simian immunodeficiency virus by mature dendritic cells induces CD4+ and CD8+ T-cell responses. J Acquir Immune Defic Syndr 2003;34:7-19.
62. Lifson JD, Rossio JL, Piatak M Jr, et al.: Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res Hum Retroviruses 2004;20:772-787.
63. Lu W, Arraes LC, Ferreira WT, and Andrieu JM: Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004;10:1359-1365.
64. Suni MA, Picker LJ, and Maino VC: Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods 1998;212:89-98.
65. Maecker H, Dunn M, Suni E, et al.: Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001;255:27-40.
66. Monaco JJ: Pathways for the processing and presentation of antigens to T cells. J Leukoc Biol 1995;57:543-547.
67. McEvers K, Elrefaei M, Norris P, et al.: Modified anthrax fusion proteins deliver HIV antigens through MHC class I and II pathways. Vaccine 2005;23:4128-4135.
68. Li Pira G, Bottone L, Ivaldi F, et al.: Recognition of CMV pp65 protein antigen by human CD4 T-cell lines induced with an immunodominant peptide pool. Hum Immunol 2004;65:537-543.
69. Zhang R, Fichtenbaum CJ, Hildeman DA, Lifson JD, and Chougnet C: CD40 ligand dysregulation in HIV infection: HIV glycoprotein 120 inhibits signaling cascades upstream of CD40 ligand transcription. J Immunol 2004;172:2678-2686.
70. Zhang R, Lifson JD, and Chougnet C: Failure of HIV-exposed CD4+ T cells to activate dendritic cells is reversed by restoration of CD40/CD154 interactions 10.1182/blood-2005-07-2731. Blood 2006;107:1989-1995.
71. Pantaleo G and Harari A: Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol 2006;6:417-423.